News | January 11, 2026
PAI Pharma acquires Nivagen to boost US injectable drug production
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Ultra-high purity surfactant for biologics and parenteral drug formulations
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
The new plant will manufacture high-quality Type I borosilicate glass tubing
Corning and SGD Pharma formed JV in June 2023 to expand pharmaceutical manufacturing in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
